A Non-Randomized, Open-Label Study to Investigate the Effects of Imatinib Mesylate on the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Trial Profile

A Non-Randomized, Open-Label Study to Investigate the Effects of Imatinib Mesylate on the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Apr 2016

At a glance

  • Drugs Imatinib (Primary) ; Paracetamol
  • Indications Chronic myeloid leukaemia
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 29 Sep 2009 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
    • 05 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 05 May 2009 Actual patient number (12) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top